1 asset in Obesity Due To Melanocortin 4 Receptor Deficiency

Therapeutic assets addressing Obesity Due To Melanocortin 4 Receptor Deficiency, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Atomoxetine Obesity Due To Melanocortin 4 Receptor Deficiency	Icahn School of Medicine at Mount Sinai	P2	NR ()